Novartis Corporation (Jobs) in $200 Million Deal with Bayer Schering Pharma on Betaseron

September 14, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

ZURICH, Sept 14 (Reuters) - Swiss pharmaceuticals group Novartis (NOVN.VX: Quote, Profile, Research) said it completed an agreement with Bayer Schering related to manufacturing rights of Novartis' Betaseron multiple scerosis treatment.

Twitter
LinkedIn
Facebook
Email
Print

Alliances Europe